Literature DB >> 30366771

Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study.

Pei-Jui Luo1, Xi-Hsuan Lin2, Chung-Chi Lin3, Jiing-Chyuan Luo4, Hsiao-Yun Hu5, Po-Hsiang Ting2, Ming-Chih Hou2.   

Abstract

BACKGROUND/
PURPOSE: We aimed to identify the risk factors of first-time occurrence of non-variceal upper gastrointestinal bleeding (UGIB) among aspirin users after adjusting for confounding factors like age, gender, underlying co-morbidities, and medications.
METHODS: Using the National Health Insurance Research Database of Taiwan and matching age, gender, underlying co-morbidities and enrollment time by propensity score, 11105 aspirin users and 11105 controls were identified for comparison from a cohort dataset of 1,000,000 randomly sampled subjects. Cox proportional hazard regression models were used to identify independent risk factors for first-time occurrence of non-variceal UGIB in the study cohort and in the aspirin users after adjusting for age, gender, underlying co-morbidities, and medications (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-2 [COX-2] inhibitors, steroids, thienopyridines, selective serotonin reuptake inhibitors, warfarin, and dipyridamole).
RESULTS: By Cox proportional hazard regression analysis, aspirin use increased the risk of first-time occurrence of UGIB (hazard ratio [HR]: 1.48; 95% confidence interval [CI]: 1.28-1.72). Age, male gender, Helicobacter pylori (H. pylori)infection, diabetes, chronic kidney disease (CKD), cirrhosis, history of uncomplicated peptic ulcer disease (PUD), and use of NSAIDs, COX-2 inhibitors, steroids, and thienopyridines were independent risk factors for UGIB among aspirin users.
CONCLUSION: In addition to age, male gender, H. pylori infection, and concomitant use of NSAIDs, COX-2 inhibitors, steroids, and thienopyridines, underlying co-morbidities including diabetes, CKD, cirrhosis, history of PUD are also important risk factors for first-time occurrence of non-variceal UGIB in aspirin users.
Copyright © 2018 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspirin; Co-morbidities; Thienopyridines; Upper gastrointestinal bleeding

Mesh:

Substances:

Year:  2018        PMID: 30366771     DOI: 10.1016/j.jfma.2018.10.007

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  4 in total

Review 1.  The Risk of Gastrointestinal Hemorrhage in Low-Dose Aspirin Users with Diabetes Mellitus: Systematic Review and Meta-Analysis.

Authors:  Yashuo Wang; Wei Wang; Bin Wang; Yunyang Wang
Journal:  Gastroenterol Res Pract       Date:  2020-08-03       Impact factor: 2.260

2.  Pathways of healthcare and antibiotics use following reported gastrointestinal illness: a cross-sectional study in rural Anhui, China.

Authors:  Xing Rong Shen; Maomao Xie; Jing Chai; Rui Feng; Jing Cheng; Rong Liu; Paul Kadetz; DeBin Wang
Journal:  BMJ Open       Date:  2019-08-20       Impact factor: 2.692

3.  Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial.

Authors:  Suzanne E Mahady; Karen L Margolis; Andrew Chan; Galina Polekhina; Robyn L Woods; Rory Wolfe; Mark R Nelson; Jessica E Lockery; Erica M Wood; Christopher Reid; Michael E Ernst; Anne Murray; Ltp Thao; John J McNeil
Journal:  Gut       Date:  2020-08-03       Impact factor: 31.793

4.  Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis.

Authors:  Surapon Nochaiwong; Chidchanok Ruengorn; Ratanaporn Awiphan; Chatree Chai-Adisaksopha; Apichat Tantraworasin; Chabaphai Phosuya; Penkarn Kanjanarat; Wilaiwan Chongruksut; Manish M Sood; Kednapa Thavorn
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.